Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

interferon gamma-primed human bone marrow-derived mesenchymal stromal cells

Human bone marrow-derived mesenchymal stromal cells (MSCs) primed with interferon gamma (IFN-g), with potential immunomodulatory activity. Upon priming with IFN-g and the administration of IFN-g-primed human bone marrow-derived MSCs, IFN-g activates the IFN-g-Janus kinase (JAK)-signal transducer and activator of transcription 1 (STAT1) signaling pathway and induces indoleamine 2,3-dioxygenase (IDO) expression in MSCs. This promotes IDO activity and enhances the inhibition of T-cell proliferation mediated by MSCs. This may enhance MSC-mediated immunosuppression and prevent graft-versus-host disease (GvHD).
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:IFN-g-primed human bone marrow-derived MSCs
IFN-g-primed MSCs
IFNγ-primed MSCs
interferon gamma-primed human bone marrow-derived MSCs
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search